+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Endothelin Receptor Antagonist"

Uptravi - Product Thumbnail Image

Uptravi

  • Report
  • October 2018
  • 18 Pages
  • Global
From
Opsumit - Product Thumbnail Image

Opsumit

  • Report
  • October 2018
  • 19 Pages
  • Global
From
Tracleer - Product Thumbnail Image

Tracleer

  • Report
  • October 2018
  • 16 Pages
  • Global
From
Letairis - Product Thumbnail Image

Letairis

  • Report
  • October 2018
  • 16 Pages
  • Global
From
Global Pulmonary Arterial Hypertension Drugs Market 2023-2027 - Product Thumbnail Image

Global Pulmonary Arterial Hypertension Drugs Market 2023-2027

  • Report
  • March 2023
  • 172 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Endothelin Receptor Antagonist (ERA) market is a subset of the cardiovascular drug market. ERA drugs are used to treat a variety of cardiovascular conditions, including hypertension, pulmonary arterial hypertension, and congestive heart failure. These drugs work by blocking the action of endothelin, a hormone that can cause constriction of the blood vessels. This helps to reduce blood pressure and improve blood flow. ERA drugs are generally well-tolerated and have few side effects. The ERA market is highly competitive, with several major pharmaceutical companies offering products. These include Amgen, Bayer, Merck, Novartis, and Pfizer. Other companies, such as Actelion, Gilead, and United Therapeutics, also offer ERA drugs. These companies are continually researching and developing new drugs to improve the treatment of cardiovascular conditions. Show Less Read more